CRYSTAL
Cetuximab + FOLFIRI in Metastatic Colorectal Cancer
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 1,198 patients with untreated metastatic colorectal cancer, cetuximab + FOLFIRI improved PFS in the KRAS/RAS wild-type subgroup compared with FOLFIRI alone.
N
1 198
Schéma
Open-label RCT
Critère
Progression-free survival
Pertinence
2
RésultatKRAS WT: PFS 9.9 vs 8.4 months (HR 0.70); OS 23.5 vs 20.0 months (HR 0.80). Post-hoc RAS WT: OS 28.4 vs 20.2 months (HR 0.69).
Van Cutsem E, et al. N Engl J Med. 2009;360(14):1408-1417; Van Cutsem E, et al. J Clin Oncol. 2011;29(15):2011-2019. 10.1056/NEJMoa0805019
Discussion et critique
Mandated KRAS/RAS testing before anti-EGFR therapy. Sidedness also matters — anti-EGFR is preferred for left-sided RAS-WT disease.